Enterprise value of top companies in non-oncology rare disease therapeutics 2017

This statistic shows the enterprise value of leading pure players in non-oncology rare disease therapeutics worldwide as of 2017. In 2017, the value of Biogen which manufactures especially multiple sclerosis therapeutics stood at nearly 70 billion U.S. dollars.

Enterprise value of leading pure players in non-oncology rare disease therapeutics worldwide as of 2017 (in million U.S. dollars)*

Loading statistic...
You need to log in to download this statistic
Register for free
Already a member?
Log in
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Release date

2017

Region

Worldwide

Survey time period

as of October 2017

Special properties

non-oncology rare disease therapeutics

Method of interview

Online survey

Supplementary notes

* All values are in current U.S. dollars.

Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Single Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 / Month *
Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract; Prices do not include sales tax.

Statistics on "Pharmaceutical trends in Europe"

Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.